Outlook Therapeutics (XTER:41O) OCF Margin %: -6,155.45% (As of Mar. 2026)


What is Outlook Therapeutics OCF Margin %?

Outlook Therapeutics XTER:41O 11 OCF Margin % is -6,155.45% as of Mar. 2026. GuruFocus rates XTER:41O with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 958 Biotechnology companies, Outlook Therapeutics ranks worse than 94.68% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Outlook Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was €-6.77 Mil. Outlook Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.11 Mil. Therefore, Outlook Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was -6,155.45%.

As of today, Outlook Therapeutics's current OCF Yield % is -18.30%.

The historical rank and industry rank for Outlook Therapeutics's OCF Margin % or its related term are showing as below:


During the past 12 years, the highest OCF Margin % of Outlook Therapeutics was -396.39%. The lowest was -3665.42%. And the median was -1069.95%.

XTER:41O's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Outlook Therapeutics OCF Margin % Related Terms

Outlook Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics OCF Margin % Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -3,664.56

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -790.65 13,519.23 1,236.24 -6,155.45

Outlook Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Outlook Therapeutics's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-44.158/1.205
=-3,664.56 %

Outlook Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.771/0.11
=-6,155.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -6,155.45% mean?
Outlook Therapeutics (XTER:41O) has a OCF Margin % of -6,155.45% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #907 out of 958 companies in the Biotechnology industry, placing it in the top 94.7%.
Is Outlook Therapeutics' OCF Margin % too high?
Outlook Therapeutics' current OCF Margin % is -6,155.45%. Based on the distribution chart, Outlook Therapeutics ranks #907 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' OCF Margin % compare to INO and CBUS?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #907 out of 958 companies for OCF Margin %. This places Outlook Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current OCF Margin % is -6,155.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (XTER:41O) has a current OCF Margin % of -6,155.45%. The current OCF Margin % is -6,155.45%. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Outlook Therapeutics (XTER:41O), the current OCF Margin % is -6,155.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges OTLK:USA41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.